An Open-Label Extension Study to Assess the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder. [EXTENSION OF 700034966]
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2013
At a glance
- Drugs Buspirone/melatonin (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- 29 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Sep 2008 New trial record.